• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

No increased risk of fatal CV events for breast cancer patients on newer hormone therapy
(Kaiser Permanente) In a new study from Kaiser Permanente, researchers found the use of aromatase inhibitors, hormone-therapy drugs used to treat patients with breast cancer, was not associated with an increased risk of fatal cardiovascular events, including heart attacks or stroke, compared with tamoxifen, another commonly prescribed anti-cancer drug that works on hormones and which has been associated with a serious risk of stroke.
Source: EurekAlert! - Cancer - April 21, 2016 Category: Cancer & Oncology Source Type: news

More Evidence That Hormone Therapy Might Not Help Women’s Hearts
Review also found raised risk of stroke for some, although timing of use may be a key factor
Source: The Doctors Lounge - Oncology - March 10, 2015 Category: Cancer & Oncology Authors: webmaster at doctorslounge.com Tags: Gynecology, Neurology, Oncology, News, Source Type: news

More Evidence That Hormone Therapy Might Not Help Women's Hearts
Review also found raised risk of stroke for some, although timing of use may be a key factor
Source: Cancercompass News: Breast Cancer - March 12, 2015 Category: Cancer & Oncology Source Type: news

Abstract 1341: Endocrine deprivation therapy increases the sensitivity of breast cancer cells to T cell-mediated lysis independently of estrogen receptor or androgen receptor status
Estrogen deprivation therapy has been used as the first line adjuvant hormonal therapy for breast cancer for over 20 years. Tamoxifen, the first drug discovered to inhibit estrogen receptor signaling, is used to treat premenopausal women with estrogen receptor positive tumors. Although tamoxifen can be therapeutic in most women with estrogen receptor positive tumors, some women do not respond and others eventually develop resistance. In addition, tamoxifen has minimal effect on the growth of estrogen receptor negative tumors, including triple negative breast cancer, which has the poorest prognosis. Furthermore, prolonged a...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Kwilas, A. R., Ardiani, A., Gameiro, S. R., Hodge, J. W. Tags: Immunology Source Type: research

Study: Hormone replacement therapy may help improve women's heart health, overall survival
(Cedars-Sinai Medical Center) Hormone replacement therapy has long been controversial as studies have associated it with health benefits and risks. While some studies suggest that it lowers the risk of osteoporosis and improves some aspects of heart health, others link it to higher risk of cancer and stroke. Now, a new imaging study suggests that women using hormone replacement therapy to relieve menopause symptoms face a lower risk of death and show lower levels of atherosclerosis compared to women who do not use hormone therapy.
Source: EurekAlert! - Cancer - March 8, 2017 Category: Cancer & Oncology Source Type: news

Cancers, Vol. 15, Pages 2316: Review of Cardiovascular Risk of Androgen Deprivation Therapy and the Influence of Race in Men with Prostate Cancer
K. Kelly Androgen deprivation therapy is the cornerstone of prostate cancer therapy. Recent studies have revealed an association between androgen deprivation therapy and cardiovascular adverse effects such as myocardial infarction and stroke. This review summarizes the available research on the cardiovascular risk of men using androgen deprivation therapy. We also discuss racial disparities surrounding both prostate cancer and cardiovascular disease, emphasizing the importance of biological/molecular and socioeconomic factors in assessing baseline risk in patients beginning androgen ablation. Based on the literature, ...
Source: Cancers - April 15, 2023 Category: Cancer & Oncology Authors: James Fradin Felix J. Kim Grace L. Lu-Yao Eugene Storozynsky William K. Kelly Tags: Review Source Type: research